AP NEWS
ADVERTISEMENT
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

World Pancreatic Cancer Diagnostic Tests Devices Pipeline Assessment 2020 - Stage of Development, Territory, Regulatory Path, Estimated Approval Date, Clinical Trials - ResearchAndMarkets.com

December 30, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Dec 30, 2020--

The “Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020” report has been added to ResearchAndMarkets.com’s offering.

ADVERTISEMENT

“Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020” provides comprehensive information about the Pancreatic Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Pancreatic Cancer Diagnostic Tests include assays of mostly antibodies released in response to a pancreatic cancer and cancer-causing proteins.

Scope

  • Extensive coverage of the Pancreatic Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Pancreatic Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Pancreatic Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

ADVERTISEMENT

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Pancreatic Cancer Overview

3 Products under Development

3.1 Pancreatic Cancer - Pipeline Products by Stage of Development

3.2 Pancreatic Cancer - Pipeline Products by Territory

3.3 Pancreatic Cancer - Pipeline Products by Regulatory Path

3.4 Pancreatic Cancer - Pipeline Products by Estimated Approval Date

3.5 Pancreatic Cancer - Ongoing Clinical Trials

4 Pancreatic Cancer - Pipeline Products under Development by Companies

4.1 Pancreatic Cancer Companies - Pipeline Products by Stage of Development

4.2 Pancreatic Cancer - Pipeline Products by Stage of Development

5 Pancreatic Cancer Companies and Product Overview

6 Pancreatic Cancer- Recent Developments

7 Appendix

Companies Mentioned

  • 2cureX AB
  • 3rd Street Diagnostics
  • A&G Pharmaceutical Inc
  • Abcodia Ltd
  • Acobiom
  • Advanced Marker Discovery SL
  • Alaunus Biosciences Inc
  • Amplified Sciences LLC
  • Anixa Diagnostics Corporation
  • Applied Proteomics Inc
  • Avant Diagnostics Inc
  • Axim Biotechnologies Inc
  • Berg LLC
  • BioMarker Strategies LLC
  • BiomaRx Inc
  • Bioprognos SL
  • Biouniversa srl
  • Cancer Research Technology Ltd
  • Captis Biotechnology Inc
  • Caris Life Sciences Inc
  • Cepheid Inc
  • Clovis Oncology Inc
  • Courtagen Life Sciences Inc
  • CS-Keys, Inc. (Inactive)
  • Di.V.A.L Toscana srl
  • Exact Sciences Corp
  • Fred Hutchinson Cancer Research Center
  • Fujirebio Diagnostics Inc
  • GlycoZym USA Inc
  • Health Discovery Corp
  • Houston Methodist Hospital
  • ImmunoCellular Therapeutics Ltd
  • Immunomedics Inc
  • Immunovia AB
  • Johns Hopkins University
  • JW Bioscience
  • Leitat Technological Center
  • Matrix-Bio Inc
  • MDNA Life Sciences Inc
  • Memorial Sloan Kettering Cancer Center
  • Merrimack Pharmaceuticals Inc
  • Metanomics Health GmbH
  • Milagen Inc
  • Myriad Genetics Inc
  • NanoScale Corp
  • Nanoview Biosciences Inc
  • NatiMab Therapeutics Srl
  • National Cheng-Kung University Hospital
  • Oncimmune (USA) LLC
  • Oncomatryx Biopharma SL
  • Onconome, Inc. (Inactive)
  • OPKO Health Inc
  • OTraces Inc
  • Oxford Gene Technology Ltd
  • Penn Medicine
  • Peri Rx Inc
  • Precision Biologics Inc
  • Preora Healthcare Inc
  • Proplex Technologies Llc
  • Protagen AG
  • Proteome Sciences Plc
  • Quanterix Corp
  • Reccan Diagnostics AB
  • RISE Life Science Corp
  • Rutgers The State University of New Jersey
  • Sanguine Diagnostics and Therapeutics Inc
  • SDIX LLC
  • Shenzhen Mindray Bio-Medical Electronics Co Ltd
  • Sienna Cancer Diagnostics Ltd
  • SomaLogic Inc
  • Stanford University
  • Taizhou ZECEN Biotech Co Ltd
  • Temple University Health System
  • Thomas Jefferson University
  • University of California San Francisco
  • University of Illinois at Chicago
  • University of Liverpool
  • University of Pennsylvania
  • University of Texas MD Anderson Cancer Center
  • University of Washington
  • US Biomarkers Inc
  • Vajra Instruments Inc
  • Vastcon Inc
  • Ventana Medical Systems Inc
  • Viomics Inc.
  • VolitionRX Ltd
  • ZORA Biosciences Oy

For more information about this report visit https://www.researchandmarkets.com/r/e86m9o

View source version on businesswire.com:https://www.businesswire.com/news/home/20201230005095/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/30/2020 05:17 AM/DISC: 12/30/2020 05:17 AM

http://www.businesswire.com/news/home/20201230005095/en